Neurocrine Biosciences Inc. (NBIX)
Neurocrine price target raised to $182 from $172 at BofA
BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices, which it highlights were significantly higher than previous modeled. BofA continues to assume the congenital adrenal hyperplasia launch will be more of a 2H25 event given new-to-market restrictions from commercial payors, but notes that Neurocrine has pledged to offer a free goods program to allow endocrinologists to get familiar with Crenessity's clinical profile.
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transformative opportunity. Peak sales are estimated at $1.47 billion by 2030. Neurocrine's pipeline includes five Phase 1, six Phase 2, and two Phase 3 programs, diversifying future growth opportunities.
US FDA approves Neurocrine Biosciences' genetic disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company with significant growth potential that it is. Ingrezza continues to deliver strong growth and cash flows for the company, and crinecerfont will be launched in early 2025.
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Todd Tushla - Vice President of Investor Relations Conference Call Participants Chris Shibutani - Goldman Sachs Paul Matteis - Stifel David Ansellem - Piper Sandler Phoebe Tan - Jefferies Tazeen Ahmad - Bank of America Securities Jay Olson - Oppenheimer Ash Verma - UBS Philip Nadeau - TD Cowen Anupam Rama - J.P. Morgan Evan Seigerman - BMO Capital Markets Cory Kasimov - Evercore ISI Carter Gould - Barclays Mohit Bansal - Wells Fargo Marc Goodman - Leerink Partners Myles Minter - William Blair Michael Riad - Morgan Stanley Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Uy Ear - Mizuho Securities Ami Fadia - Needham Operator Good day, everyone and welcome to Neurocrine Biosciences' reports Third Quarter Results.
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine's experimental drug misses primary goal in schizophrenia trial
Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
Why Neurocrine Biosciences Stock Was Tumbling This Week
The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
